Compare · NVO vs RANI
NVO vs RANI
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rani Therapeutics Holdings Inc. (RANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RANI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.47B, about 2173.8x RANI ($95.9M).
- Over the past year, NVO is down 3.6% and RANI is up 43.8% - RANI leads by 47.4 points.
- RANI has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for RANI).
- Company
- Novo Nordisk A/S
- Rani Therapeutics Holdings Inc.
- Price
- $47.08-8.73%
- $0.78-5.46%
- Market cap
- $208.47B
- $95.9M
- 1M return
- -3.49%
- +1.67%
- 1Y return
- -3.57%
- +43.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RANI
- Director Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)
- Chief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)
- Chief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Chief Financial Officer Maestas Nicholas
- Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-8 filed by Rani Therapeutics Holdings Inc.
- Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
- Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
- SEC Form 3 filed by new insider Maestas Nicholas